We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App

Diasorin Molecular’s New Multiplex COVID-19/Influenza Test Receives CE Mark

By LabMedica International staff writers
Posted on 22 Sep 2021
Print article
DiaSorin Molecular (Cypress, CA, USA) has CE marked its Simplexa COVID-19 & Flu A/B Direct kit.

The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus and influenza B virus from the same patient sample in one reaction well. The assay is designed for use on the LIAISON MDX and is run directly from nasopharyngeal swabs (NPS) without the need for off board extraction.

The assay provides confidence in results through broad strain coverage. Over 80 influenza strains were validated including all of the strains in the CDC panels of the last three years. Emerging SARS-CoV-2 variants including the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621) variants were also evaluated to ensure diagnostic coverage.

Flu was nearly nonexistent during the 2020/2021 season, which means that the normally high levels of immunity are much lower in the community, leading to the risk for a potentially high spread next season. The upcoming respiratory illness season will be complicated by the presence of SARS-CoV-2 also circulating in the community. The Simplexa COVID-19 & Flu A/B Direct kit provides the ability for laboratories to efficiently run a single, accurate test to detect the most likely causes of respiratory illness during this flu season. This is especially critical given the difficulty to identify the etiology of the infection based solely on a patient’s clinical presentation. Accurate diagnosis of the virus causing infection is critical for the management of therapeutic regimens along with infection control efforts.

"We are excited to expand our product offering with the launch of this combination kit for detection of SARS-CoV-2 and influenza that can help address concerns in anticipation of this upcoming flu season" said Michelle Tabb, chief scientific officer of DiaSorin Molecular. “We are committed to providing flexible testing options with the new combo kit in addition to our stand-alone COVID-19 assay as well as the triplex for Flu A, Flu B and RSV in order to meet laboratory's evolving needs as the world comes back to a new normal.”
Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2
Automated Urinalysis Solution
DxU Iris Workcell
Gold Supplier
Fully Automated Batch Immunoanalyzer
Real Time PCR Platform

Print article



view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more


view channel

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more


view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more


view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.